eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
1/2021
vol. 72
 
Share:
Send email
Share:
abstract:
Original paper

Prognostic and clinicopathological implications of expression of Beclin-1 and hypoxia-inducible factor 1α in serous ovarian carcinoma: an immunohistochemical study

Mohamed Alabiad
1
,
Ola Harb
1
,
Doaa Mandour
2
,
Rehab Hemeda
2
,
Rham Z. Ahmed
3
,
Ahmed El-Taher
4
,
Gamal Osman
4
,
Amany Shalaby
5
,
Amr A.A. Alnemr
6
,
Mostafa T. Abdelfattah
6

  1. Pathology Department, Faculty of Medicine, Zagazig University, Egypt
  2. Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Zagazig University, Egypt
  3. Medical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
  4. General Surgery Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
  5. Histology and Cell Biology Department, Faculty of Medicine, Tanta University, Tanta, Egypt
  6. Obstetrics and Gynecology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Pol J Pathol 2021; 72 (1): 23-38
DOI: https://doi.org/10.5114/pjp.2021.106441
Online publish date: 2021/05/31
View full text Get citation
 
PlumX metrics:
Serous ovarian carcinoma (SOC) is an ovarian cancer with a high fatality rate. Therefore, a lot of researchers have tried to identify novel prognostic biomarkers which might improve the patient prognosis. The aims of the study were to detect the tissue protein expression of Beclin-1 in addition to HIF-1α in SOC patients, to evaluate the relationship between their expression, the clinicopathological parameters, patients’ prognosis, and the relation to chemotherapy resistance in SOC. We evaluated the expression of Beclin-1 in addition to HIF-1α in 60 patients with SOC using immunohistochemistry, followed all patients for about 36 months, analyzed associations between both markers' expression, clinicopathological data, and patients’ prognosis. Beclin-1 expression was related to low grade (p = 0.002), early SOC stage, absence of peritoneal spread (p = 0.006), and absence of lymph nodes, and distant metastases (p = 0.004 and < 0.001 respectively), while HIF-1α expression was associated with higher grade and stage (p = 0.007), and presence of nodal and distant metastases (p < 0.001 and = 0.012 respectively). High Beclin-1 expression and low HIF-1α expression were positively associated with good response to chemotherapy (p = 0.047 and p = 0.022 respectively), a lower recurrence rate after successful therapy (p = 0.006 and < 0.001 respectively), and increased three-year recurrence-free and overall survival rates (p < 0.001). In SOC patients; Beclin-1 is a good prognostic marker, while HIF-1α is a poor prognostic marker.
keywords:

serous ovarian carcinoma, Beclin-1, HIF-1α, survival, immunohistochemistry
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.